Javascript must be enabled to continue!
Evaluation of CD137 as a costimulatory receptor in multiple myeloma
View through CrossRef
Multiple Myeloma (MM) is a plasma cell malignancy characterized by terminally differentiated plasma cells residing in the bone marrow. It is the second most common hematological malignancy in the United States. Despite recent advances in treatment strategies for multiple myeloma, the disease is incurable. Next-generation MM therapies such as T-cell redirection involve the use of bi-specific antibodies to redirect T-cells against tumor cells. The activation of T-cells by these bi-specific antibodies, also induces expression of costimulatory receptors such as CD137, which is an attractive target for immunotherapy. CD137 agonists stimulate this by potentiating costimulatory pathways on T-cells, leading to enhanced proliferation, survival, persistence, and improved memory differentiation, which is hypothesized to lead to improved tumor efficacy. Here, we evaluated the expression of CD137 on T-cells after treatment with two MM bispecific antibodies, GPRC5DxCD3 and BCMAxCD3. In addition, CD137 expression was evaluated on NK cells after treatment with effector function active anti-CD38 and anti-SLAMF7 on MM cells. Antibody-mediated stimulation of T-cells and NK cells by the effector function antibodies resulted in the initial expression of CD137 after which it gradually decreased with time. To explore strategies for augmenting CD137 expression, we cultured T-cells or NK cells in the presence of human recombinant cytokines (IL-2, IL-15, IFN-y, or TNF-a). While cytokines alone did not induce CD137 expression, IL-15 treatment resulted in the upregulation of activation markers in T-cells (CD25) or NK cells (NKG2D). Subsequently, T-cells were stimulated with activation antibodies (anti-CD3, anti-CD3/anti-CD28, or anti-TCR) and treated with IL-15 to investigate the expression of CD137. This resulted in a significant increase in CD137 expression, indicating that the combination of IL-15 and effector function antibodies may serve as an effective strategy to boost CD137.
Title: Evaluation of CD137 as a costimulatory receptor in multiple myeloma
Description:
Multiple Myeloma (MM) is a plasma cell malignancy characterized by terminally differentiated plasma cells residing in the bone marrow.
It is the second most common hematological malignancy in the United States.
Despite recent advances in treatment strategies for multiple myeloma, the disease is incurable.
Next-generation MM therapies such as T-cell redirection involve the use of bi-specific antibodies to redirect T-cells against tumor cells.
The activation of T-cells by these bi-specific antibodies, also induces expression of costimulatory receptors such as CD137, which is an attractive target for immunotherapy.
CD137 agonists stimulate this by potentiating costimulatory pathways on T-cells, leading to enhanced proliferation, survival, persistence, and improved memory differentiation, which is hypothesized to lead to improved tumor efficacy.
Here, we evaluated the expression of CD137 on T-cells after treatment with two MM bispecific antibodies, GPRC5DxCD3 and BCMAxCD3.
In addition, CD137 expression was evaluated on NK cells after treatment with effector function active anti-CD38 and anti-SLAMF7 on MM cells.
Antibody-mediated stimulation of T-cells and NK cells by the effector function antibodies resulted in the initial expression of CD137 after which it gradually decreased with time.
To explore strategies for augmenting CD137 expression, we cultured T-cells or NK cells in the presence of human recombinant cytokines (IL-2, IL-15, IFN-y, or TNF-a).
While cytokines alone did not induce CD137 expression, IL-15 treatment resulted in the upregulation of activation markers in T-cells (CD25) or NK cells (NKG2D).
Subsequently, T-cells were stimulated with activation antibodies (anti-CD3, anti-CD3/anti-CD28, or anti-TCR) and treated with IL-15 to investigate the expression of CD137.
This resulted in a significant increase in CD137 expression, indicating that the combination of IL-15 and effector function antibodies may serve as an effective strategy to boost CD137.
Related Results
CD137-CD137L Signaling Affects Angiogenesis by Mediating Phenotypic Conversion of Macrophages
CD137-CD137L Signaling Affects Angiogenesis by Mediating Phenotypic Conversion of Macrophages
Background:
Angiogenesis in atherosclerotic plaque is an important factor causing plaque hemorrhage, vulnerability, and rupture, and different phenotypes of macrophages...
The role of soluble CD137 in development of liver cirrhosis among hepatitis B virus infected individuals
The role of soluble CD137 in development of liver cirrhosis among hepatitis B virus infected individuals
Introduction: Viral and tumor management are mediated by the production of CD137 as a co-receptor for T cells. Objective: The purpose of the research is to examine the link between...
CD137 in tuberculosis: a scoping review of an emerging immune checkpoint at the crossroads of diagnosis, prognosis, and therapy
CD137 in tuberculosis: a scoping review of an emerging immune checkpoint at the crossroads of diagnosis, prognosis, and therapy
Introduction
CD137 (4-1BB), a member of the tumour necrosis factor (TNF) receptor superfamily, plays a key role in T-cell activation, sur...
CD137 agonist induces gastric cancer cell apoptosis by enhancing the functions of CD8+ T cells via NF-κB signaling
CD137 agonist induces gastric cancer cell apoptosis by enhancing the functions of CD8+ T cells via NF-κB signaling
Abstract
Background: CD137 is a target for tumor immunotherapy. However, the role of CD137 in gastric cancer (GC), especially in inducing GC cell apoptosis, has not been st...
Seorang laki-laki dewasa muda dengan multiple myeloma monoklonal gamopati lambda: sebuah laporan kasus
Seorang laki-laki dewasa muda dengan multiple myeloma monoklonal gamopati lambda: sebuah laporan kasus
Introduction: Multiple myeloma is the second most common hematological malignancy after non-Hodgkin's lymphoma with a case prevalence in Prof. Dr. I.G.N.G. Ngoerah Hospital for the...
Data from A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance
Data from A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance
<div>Abstract<p>The NF-κB signaling pathway plays key roles in inflammation and the pathogenesis of many solid and hematologic malignancies, including multiple myeloma,...
Data from A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance
Data from A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance
<div>Abstract<p>The NF-κB signaling pathway plays key roles in inflammation and the pathogenesis of many solid and hematologic malignancies, including multiple myeloma,...
Multiplex Immunofluorescence reveals specific subsets of immune cell populations expressing CD137/TNFRSF9 as predictors of unfavorable outcomes in Hodgkin Lymphoma
Multiplex Immunofluorescence reveals specific subsets of immune cell populations expressing CD137/TNFRSF9 as predictors of unfavorable outcomes in Hodgkin Lymphoma
The tumor microenvironment (TME) is a crucial determinant of tumor growth, progression, and resistance to chemotherapy in cancer, with classical Hodgkin's lymphoma (cHL) being one ...

